PRE Stock Forecast & Price Target

Prenetics Global is supported by a powerful combination of financing, growth visibility, and improving unit economics, highlighted by the closing of $1 billion in growth financing from General Catalyst’s CVF, which can fund up to 70% of IM8’s marketing spend with no equity dilution. IM8’s momentum is equally compelling, with preliminary record revenue of about $17 million in June, FY26 revenue guidance raised to $210 million-$220 million, ARR of about $200 million as of May 31, and a projected path to more than $400 million in FY27, while quarterly subscriptions have lifted LTV/CAC to 3:1 and improved cash collection. Its clinically validated, NSF-certified products, strong influencer-led brand, and cash-and-investments balance of about $139.7 million as of 5/31 together support a durable, scalable growth story that appears undervalued relative to peers.

Prenetics Global is exposed to a fragile growth model because sustainable revenue depends on converting customers into paying subscribers and retaining them, while shifts in consumer preferences, weaker renewal rates, or softer discretionary spending could quickly hurt results. The company is still balancing growth against profitability as sales and marketing remain its largest expense, and higher acquisition costs tied to quarterly subscriptions may not be offset by better lifetime value, especially amid volatile digital ad rates and global fulfillment costs. Its outlook is further pressured by FDA non-approval of dietary supplements, intense competition, Hong Kong and China-related geopolitical risk, and governance concerns as a Nasdaq foreign private issuer and controlled company with more than 50% voting power held by Chairman and CEO Danny Yeung.